For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Attruby represents a true breakthrough . These groundbreaking therapies stabilize the transthyretin protein, slowing its destructive build-up and alleviating the im